AdipoGen Life Sciences

L-NMMA . monoacetate

CHF 30.00
In stock
AG-CR1-3578-M0055 mgCHF 30.00
AG-CR1-3578-M02525 mgCHF 70.00
AG-CR1-3578-M100100 mgCHF 240.00
AG-CR1-3578-G0011 gCHF 650.00
More Information
Product Details
Synonyms NG-Monomethyl-L-arginine . monoacetate
Product Type Chemical


MW 188.2 . 60.1
Merck Index 14: 6022
CAS 53308-83-1
RTECS RM2982000
Purity Chemicals ≥99% (TLC)
Appearance White to off-white solid.
Solubility Soluble in water, ethanol, methanol or DMSO.
Smiles CC([O-])=O.CNC(=N)NCCC[C@H]([NH3+])C(O)=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Endothelium-derived relaxing factor inhibitor. Inhibits the generation of NO from arginine.
  • Competitive, irreversible non-selective inhibitor of all three NOS I, II, and III isoforms (eNOS, iNOS and nNOS).
  • Inhibits the synthesis of nitric oxide (NO) in a dose-dependent and enantiospecific fashion.
  • Useful tool to study the role and the effects of NO in cardiovascular and gastrointestinal disorders, hypertension, diabetes, septic shock, inflammation, infection, stroke and neurodegenerative disorders.
Product References
  1. Identification of arginine as a precursor of endothelium-derived relaxing factor: I. Sakuma, et al.; PNAS 85, 8664 (1988)
  2. NG-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo?: K. Aisaka, et al.; BBRC 160, 881 (1989)
  3. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation: D.D. Rees, et al.; Br. J. Pharmacol. 96, 418 (1989)
  4. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo: D.D. Rees, et al.; Br. J. Pharmacol. 101, 746 (1990)
  5. Role of endothelium-formed nitric oxide on vascular responses: J. Marin J & C.F. Sanchez-Ferrer; Gen. Pharmacol. 21, 575 (1990)
  6. Inactivation of macrophage nitric oxide synthase activity by N(G)-methyl-L-arginine: N.M. Olken, et al.; BBRC 177, 828 (1991)
  7. Nitric oxide: an endogenous modulator of leukocyte adhesion: P. Kubes, et al.; PNAS 88, 4651 (1991)
  8. Macrophage nitric oxide mediates immunosuppression in infectious inflammation: T.K. Eisenstein, et al.; Immunobiology 191, 493 (1994) (Review)
  9. N-nitro-L-arginine and N-monomethyl-L-arginine exhibit a differential pattern of inactivation toward the three nitric oxide synthases: D.W. Reif & C.A. McCreedy; Arch. Biochem. Biophys. 320, 170 (1995)
  10. Cell death, survival and proliferation in Tetrahymena thermophila. Effects of insulin, sodium nitroprusside, 8-Bromo cyclic GMP, NG-methyl-L-arginine and methylene blue: S.T. Christensen; Cell Biol. Int. 20, 653 (1996) (Review)
  11. Nitric oxide synthase inhibitors: Amino acids. O.W. Griffith & R.G. Kilbourn; Methods Enzymol. 268, 375 (1996)
  12. Selective inhibitors of neuronal nitric oxide synthase-is no NOS really good NOS for the nervous system? P.K. Moore & R.L. Handy; TIPS 18, 204 (1997) (Review)
  13. Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance: K. Toutouzas; Horm. Metab. Res. 40, 655 (2008) (Review)
  14. Insulin resistance after hypertension induced by the nitric oxide synthesis inhibitor L-NMMA in rats: A.D. Baron; Am. J. Physiol. 269, E709 (1995)
  15. The NO synthase inhibitors L-Name and L-NMMA, but not L-arginine, block the mammalian nicotinic acetylcholine receptor channel: M Scheller; Toxicol. Lett. 100-101, 109 (1998)
  16. Induction of apoptosis by L-NMMA, via FKHRL1/ROCK pathway in human gastric cancer cells: Y.Z. Wang & Z.Q. Feng; Biomed. Environ. Sci. 19, 285 (2006)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.